Victoria M. Garbitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Victoria M. Garbitt has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Xin Shi
Department of Medicine, Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona
34 shared publications - Marta Chesi
Mayo Clinic Arizona
34 shared publications - Yuan Xiao Zhu
Department of Medicine, Mayo Clinic, Phoenix, AZ
34 shared publications - Anna V. Roschke
Genetics Branch, Center for Cancer Research, NCI, Bethesda, Maryland
33 shared publications - Benjamin Gabriel Barwick
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
33 shared publications - Caleb K. Stein
Mayo Clinic 3 Division of Hematology and Oncology Scottsdale, Arizona
33 shared publications
Latest Publications
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Multi-variate analysis of BATF, BATF2, and BATF3 expression
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Multi-variate analysis of BATF, BATF2, and BATF3 expression
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S11 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Figures 1-11, which support data and conclusions provided in the main figures
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S11 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Figures 1-11, which support data and conclusions provided in the main figures
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Gene expression associated with BATF in NDMM bone marrow CoMMpass samples
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Gene expression associated with BATF in NDMM bone marrow CoMMpass samples
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Gene expression associated with BATF in NDMM bone marrow CoMMpass samples
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Gene expression associated with BATF in NDMM bone marrow CoMMpass samples
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 5 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
GSEA of genes associated with BATF expression in CoMMpass
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 5 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
GSEA of genes associated with BATF expression in CoMMpass
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Differential Accessible Regions in JJN3 and KMS11
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Differential Accessible Regions in JJN3 and KMS11
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Multi-variate analysis of BATF, BATF2, and BATF3 expression
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Multi-variate analysis of BATF, BATF2, and BATF3 expression
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S11 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Figures 1-11, which support data and conclusions provided in the main figures
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S11 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Supplementary Figures 1-11, which support data and conclusions provided in the main figures